Related Experiment Video
Updated: Sep 15, 2025
Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
Early Clinical Response is Associated With a Decreased Risk of Recurrent Pseudomonas aeruginosa Ventilator-Associated
Alex S Huang1,2, Jing J Zhao3, Ryan Gumbleton3
1Department of Pharmacy, Detroit Receiving Hospital, Detroit, MI, USA.
Background:
Current data suggest that short-course therapy for Pseudomonas aeruginosa ventilator-associated pneumonia (PA-VAP) may increase the risk of recurrent pneumonia. To decrease antibiotic exposure without adversely impacting clinical outcomes, risk stratification based on clinical response may identify optimal candidates for short-course therapy.
Objective:
The purpose of this study was to determine whether early response to therapy correlated with the risk of recurrence in patients with PA-VAP.
Methods:
This was a retrospective cohort study of patients with PA-VAP admitted to the Detroit Medical Center from January 2020 to July 2022. Those with improvements in at least 2 out of 3 objective measures of clinical response (PaO2/FiO2, fever, and leukocyte count) at 72 hours after therapy initiation were classified as early responders. The primary outcome was PA-VAP recurrence within 28 days of initial VAP onset.
Results:
A total of 73 patients were included in the analysis: early response (n = 43) and delayed response (n = 30). Patients with an early response had a significantly decreased risk of 28-day PA-VAP recurrence compared to those with a delayed response (21% vs 43%, P = 0.04). Multivariable logistic regression found that PaO2/FiO2 > 240 mm Hg at 72 hours was associated with a decreased risk of 28-day PA-VAP recurrence (odds ratio [OR] = 0.25, 95% confidence interval [CI] = 0.07 to 0.90), whereas duration of antibiotics ≤8 days was associated with an increased risk of 28-day PA-VAP recurrence (OR = 4.74, 95% CI = 1.31 to 17.18).
Conclusion And Relevance:
This study found that early clinical response and improvement in PaO2/FiO2 were associated with a decreased risk of PA-VAP recurrence. Individualized treatment durations based on clinical response may allow clinicians to safely utilize shorter antibiotic courses for PA-VAP.
Insights
Early clinical response in patients with Pseudomonas aeruginosa ventilator-associated pneumonia (PA-VAP) is linked to a lower risk of recurrence. This suggests individualized antibiotic treatment durations based on patient response may be safe and effective for PA-VAP management.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pulmonary Medicine
Background:
- Short-course antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia (PA-VAP) may increase recurrence risk.
- Risk stratification based on clinical response could enable shorter antibiotic courses without compromising outcomes.
Purpose of the Study:
- To investigate the correlation between early therapeutic response and the risk of PA-VAP recurrence.
- To identify clinical markers for optimizing antibiotic treatment duration in PA-VAP.
Main Methods:
- Retrospective cohort study of 73 patients with PA-VAP (January 2020 - July 2022).
- Early responders defined by improvement in PaO2/FiO2, fever, and leukocyte count within 72 hours.
- Primary outcome: PA-VAP recurrence within 28 days.
Main Results:
- Early responders (n=43) had significantly lower 28-day recurrence rates compared to delayed responders (n=30) (21% vs 43%, P=0.04).
- Improved PaO2/FiO2 (>240 mm Hg) at 72 hours was associated with decreased recurrence (OR=0.25).
- Antibiotic duration ≤8 days correlated with increased recurrence risk (OR=4.74).
Conclusions:
- Early clinical response and improved PaO2/FiO2 predict a lower risk of PA-VAP recurrence.
- Individualized antibiotic durations based on clinical response may allow for safe, shorter treatment courses in PA-VAP.
- This approach could help reduce antibiotic exposure and resistance while maintaining efficacy.
More Related Videos
04:32Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Pneumonia III: Complications and Assessment
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...